Syngene International Limited, a leading global contract research, development, and manufacturing services organization, announced expansion of its existing research campus in the cluster. The Company envisages an investment up to Rs. 788 crores to develop the expanded campus in Genome Valley to its full potential, including the creation of up to 1000 jobs in science, in the next 5 years. The ground-breaking ceremony was attended by Minister KT Rama Rao.
Syngene’s existing research facility in Genome Valley was inaugurated in 2020 with a 52,000 sq. ft facility and has now grown four times to an impressive 2,00,000 sq. ft housing more than 900 scientists. The research carried out on the site focuses on discovery chemistry and biology, primarily for the global pharmaceutical industry. Minister Mr. KT Rama Rao also inaugurated the State-of-the-art PROTAC laboratory that conducts leading edge research into disease-causing proteins, which lie at the heart of diseases such as cancer and also, a Central Compound Management facility which serves as a central storage facility for all compounds synthesized by Syngene scientists.
Both facilities of Syngene are based out of Genome Valley, which is the premier Life Sciences hub in Asia. Genome Valley is home to more than 200 companies with a scientific workforce of about 25,000 professionals including presence of the marquee global names like Novartis, Ferring Pharma, Chemo, DuPont, Ashland, United States Pharmacopeia, Lonza amongst many others. Genome Valley has emerged as a global hub for life sciences and biotechnology, bringing together leading research institutions, biotech companies and talented professionals.
Speaking on the occasion, Minister KTR said “I’m proud of the legacy that we have established in the Life Sciences sector in the State. Syngene’s expansion is a testament to the tremendous opportunities and support that our State provides.” The minister added that Genome Valley aims to facilitate the necessary infrastructure and support systems to enable pioneering life science R&D activities. “This expansion aligns with our vision to attract and nurture top talent, drive innovation and foster economic development,” he added.
Kiran Mazumdar Shaw, Chairperson of Syngene International Ltd., said, “We are delighted to expand Syngene’s operations in Genome Valley with the addition of a large new research and development facility which will create additional jobs and contribute to the growth of the biotech industry. As a part of our commitment to drive innovation and strengthen the biotech ecosystem of the country, we will be investing up to INR 788 crores over the next few years, in Genome Valley in Hyderabad. I extend my congratulations to the Government of Telangana for their visionary efforts towards setting up a world class biotech hub in Hyderabad.”
Jonathan Hunt, Managing Director and Chief Executive Officer of Syngene International said, “Scientific innovation does not happen in isolation: it is a multi-dimensional process and we have been able to make all the connections that we need at Genome Valley. Syngene started operations here in 2020 with the inauguration of our first research laboratory. Since then, we have gradually increased our presence encouraged by the good infrastructure and availability of scientific talent, which is ideal for fast-growing organizations like Syngene. In the last 3 years, our employee base has grown to over 900 scientists. In the next expansion phase, we plan to build world-class research laboratories primarily focusing on drug discovery that will create up to another 1000 jobs.”